Repairing the parkinsonian brain with neurotrophic factors
- PMID: 21144600
- DOI: 10.1016/j.tins.2010.11.001
Repairing the parkinsonian brain with neurotrophic factors
Abstract
No therapy exists to slow down or prevent Parkinson's disease (PD), a debilitating neurodegenerative disorder. Neurotrophic factors (NTFs) emerged as promising disease-modifying agents in PD and are currently under clinical development. We argue that efforts in three research areas must converge to harness the full therapeutic power of NTFs. First, the physiological roles of NTFs in aging dopaminergic neurons must be comprehensively understood. Second, the mechanisms underlying the neuroprotective, neurorestorative and stimulatory effects of NTFs on diseased neurons need to be defined. Third, improved brain delivery of NTFs and new ways to stimulate NTF signaling are required to achieve clinical benefits. In this review, we discuss progress in these areas and highlight emerging concepts in NTF biology and therapy.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy.Hum Gene Ther. 2015 Aug;26(8):550-9. doi: 10.1089/hum.2015.065. Hum Gene Ther. 2015. PMID: 26176331 Review.
-
The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.Exp Neurol. 1993 Nov;124(1):103-18. doi: 10.1006/exnr.1993.1181. Exp Neurol. 1993. PMID: 8282068 Review.
-
Viral vector delivery of neurotrophic factors for Parkinson's disease therapy.Expert Rev Mol Med. 2015 May 13;17:e8. doi: 10.1017/erm.2015.6. Expert Rev Mol Med. 2015. PMID: 25997719 Review.
-
Neurotrophic factor therapy for Parkinson's disease.Prog Brain Res. 2010;184:237-64. doi: 10.1016/S0079-6123(10)84013-0. Prog Brain Res. 2010. PMID: 20887879 Review.
-
Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease.FEBS Lett. 2015 Dec 21;589(24 Pt A):3739-48. doi: 10.1016/j.febslet.2015.09.031. Epub 2015 Oct 9. FEBS Lett. 2015. PMID: 26450777 Review.
Cited by
-
Roles of Rheb(S16H) in substantia nigra pars compacta dopaminergic neurons in vivo.Biomed Rep. 2015 Mar;3(2):137-140. doi: 10.3892/br.2014.397. Epub 2014 Dec 9. Biomed Rep. 2015. PMID: 25798236 Free PMC article.
-
Exercise-Induced Neuroprotection and Recovery of Motor Function in Animal Models of Parkinson's Disease.Front Neurol. 2019 Nov 1;10:1143. doi: 10.3389/fneur.2019.01143. eCollection 2019. Front Neurol. 2019. PMID: 31736859 Free PMC article. Review.
-
Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Elevates Stimulus-Evoked Release of Dopamine in Freely-Moving Rats.Mol Neurobiol. 2018 Aug;55(8):6755-6768. doi: 10.1007/s12035-018-0872-8. Epub 2018 Jan 18. Mol Neurobiol. 2018. PMID: 29349573 Free PMC article.
-
Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors.Mol Neurobiol. 2017 Dec;54(10):7722-7735. doi: 10.1007/s12035-016-0244-1. Epub 2016 Nov 14. Mol Neurobiol. 2017. PMID: 27844282
-
Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.P T. 2015 Oct;40(10):668-79. P T. 2015. PMID: 26535023 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
